Takeda furthers oncology ambitions with IDM acquisition
This article was originally published in Scrip
Executive Summary
Takeda is to acquire the small US oncology company IDM Pharma for around $75 million. The Japanese firm will pay $2.64 per share for 100% of IDM's outstanding common stock in an all-cash tender offer.